Domestic drug makers' rush to antihypertensive and antidiabetic drugs market

Stimulated by the government policy to provide preferential treatment for generic and bioequivalence-tested drugs, a number of drug makers are rushing to introduce generic versions of Pfizer's Novarsc and Handok Pharm's Amaryl in the hope of acquiring large share of the off-patent drugs market.

1) Amolodipine salts: A total of 15 amolodipine preparations in screening of bioequivalence protoc...